Table 2. Subgroup analysis for accuracy of PLA2R-AB for MN detection.

Subgroup	N	Sensitivity	Specificity	DOR	AUC
Race
Caucasian	10	0.80(0.62,0.91)	1.00(0.98,1.00)	1297	0.99(0.97–0.99)
Asian	5	0.72(0.67,0.77)	0.91(0.84,0.95)	26	0.91(0.88–0.93)
Sample size
<100 subjects	6	0.82(0.66,0.91)	0.97(0.78,1.00)	147	0.94(0.92–0.96)
> = 100 subjects	9	0.76(0.59,0.88)	0.99(0.97,1.00)	465	0.97(0.96–0.99)
Control
Patients	9	0.80(0.64,0.90)	0.98(0.89,1.00)	220	0.95(0.93–0.97)
Health	6	0.75(0.55,0.88)	1.00(0.98,1.00)	914	1.00(0.99–1.00)
Method
Western blotting	9	0.68(0.62,0.73)	0.97(0.93,0.99)	73	0.84(0.80–0.87)
Imunofluorescence	4	0.74(0.37,0.93)	0.99(0.78,1.00)	451	0.98(0.96–0.99)
ELISA	1	-	-	-	-
Test interval
No	8	0.68(0.62,0.73)	0.95(0.86,0.98)	39	0.78(0.74–0.81)
After biopsy test	7	0.86(0.65,0.96)	1.00(0.98,1.00)	8710	1.00(0.99–1.00)
Funding by
Government foundation	9	0.70(0.56,0.81)	0.99(0.90,1.00)	177	0.89(0.86–0.92)
Corporation or no funding	6	0.88(0.76,0.95)	0.99(0.96,1.00)	843	0.99(0.98–1.00)